All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Visual abstract | PSOARING 3: 52-week safety and efficacy of tapinarof cream
By Ella Dixon
The Psoriasis and Psoriatic Arthritis Hub is happy to present a visual abstract summarizing key findings from the phase III PSOARING 3 trial evaluating the long-term efficacy and safety of tapinarof 1% cream in patients with plaque psoriasis. Included patients had received 12 weeks of prior treatment with tapinarof or vehicle cream PSOARING 1 or 2 trials.
Overall, patients were enrolled for a total of 52 weeks (12 weeks in PSOARING 1 or 2, plus 40 weeks in PSOARING 3).1 In PSOARING 1 and 2, patients were randomly assigned 2:1 to tapinarof cream and vehicle.2 In PSOARING 3, patients received tapinarof until a PGA score of 0 was achieved and were monitored for remittive effect, with a total of 40.9% of patients achieved a PGA of 0 at least once during the trial.1
Results from the PSOARING 3 trial demonstrate the consistent safety profile and sustained efficacy of tapinarof cream at 52 weeks.
- Strober B, Gold LS, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial. J Am Acad Dermatol. 2022; 87(4):800-806. DOI: 1016/j.jaad.2022.06.1171
- Lebwohl MG, Gold LS, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219-2229. DOI: 1056/NEJMoa2103629
Your opinion matters
6 votes - 85 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox